[Congressional Record Volume 169, Number 120 (Thursday, July 13, 2023)]
[Senate]
[Page S2667]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 532. Mr. RUBIO (for himself and Mr. Coons) submitted an amendment 
intended to be proposed by him to the bill S. 2226, to authorize 
appropriations for fiscal year 2024 for military activities of the 
Department of Defense, for military construction, and for defense 
activities of the Department of Energy, to prescribe military personnel 
strengths for such fiscal year, and for other purposes; which was 
ordered to lie on the table; as follows:

       At the appropriate place, insert the following:

     SEC. __. REVIEW OF DOMESTIC BIOPHARMACEUTICAL MANUFACTURING 
                   CAPABILITIES.

       (a) In General.--The Secretary of Health and Human Services 
     (referred to in this section as the ``Secretary''), in 
     cooperation with the Director of the Biomedical Advanced 
     Research and Development Authority, shall seek to enter into 
     an agreement with the National Institute for Innovation in 
     Manufacturing Biopharmaceuticals to perform the services 
     described in subsection (b).
       (b) Review and Recommendations.--Under an agreement 
     described in subsection (a) between the Secretary, the 
     Director of the Biomedical Advanced Research and Development 
     Authority, and the National Institute for Innovation in 
     Manufacturing Biopharmaceuticals, the National Institute for 
     Innovation in Manufacturing Biopharmaceuticals shall--
       (1) review current domestic biopharmaceutical manufacturing 
     capacity at the Department of Health and Human Services and 
     such department's adaptability to various threats;
       (2) draft recommendations for developing, demonstrating, 
     deploying, and advancing new domestic biopharmaceutical 
     manufacturing technologies that address gaps identified under 
     paragraph (1) and align Federal technologies with 
     technologies available to the private sector, including 
     through the new BioMAP initiative of the Biomedical Advanced 
     Research and Development Authority; and
       (3) identify other opportunities and priorities to improve 
     the United States public health and medical preparedness and 
     response capabilities and domestic biopharmaceutical 
     manufacturing capabilities.
                                 ______